1. A Pan-Cancer Study of KMT2 Family as Therapeutic Targets in Cancer. (11th January 2022) Authors: Zhu, Jiamin; Liu, Zhili; Liang, Xiao; Wang, Lu; Wu, Dan; Mao, Weidong; Shen, Dong Other Names: Wang Jimei Academic Editor. Journal: Journal of oncology Issue: Volume 2022(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. (August 2020) Authors: Lu, Shun; Chen, Gongyan; Sun, Yuping; Sun, Sanyuan; Chang, Jianhua; Yao, Yu; Chen, Zhendong; Ye, Feng; Lu, Junguo; Shi, Jianhua; He, Jianxing; Liu, Xiaoqing; Zhang, Yiping; Liu, Zhihua; Fang, Jian; Cheng, Ying; Hu, Chunhong; Mao, Weidong; Hu, Yanping; Gong, Youling Journal: Lung cancer Issue: Volume 146(2020) Page Start: 252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Alpinumisoflavone suppresses human Glioblastoma cell growth and induces cell cycle arrest through activating peroxisome proliferator‐activated receptor‐γ. Issue 11 (8th January 2020) Authors: He, Lijuan; Shen, Dong; Li, Jianmei; Mao, Weidong Journal: Anatomical record Issue: Volume 303:Issue 11(2020) Page Start: 2801 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. Issue 2 (10th November 2020) Authors: Chen, Xiaofeng; Wu, Xiaofeng; Wu, Hao; Gu, Yanhong; Shao, Yang; Shao, Qianwen; Zhu, Feipeng; Li, Xiao; Qian, Xiaofeng; Hu, Jun; Zhao, Fengjiao; Mao, Weidong; Sun, Jing; Wang, Jian; Han, Gaohua; Li, Changxian; Xia, Yongxiang; Seesaha, Poshita Kumari; Zhu, Dongqin; Li, Huajun Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study. Issue 15 (16th April 2021) Authors: Zhu, Jiamin; Liang, Xiao; Wu, Dan; Chen, Shusen; Yang, Baixia; Mao, Weidong; Shen, Dong Other Names: Zhou. Jian-Guo section editor. Journal: Medicine Issue: Volume 100:Issue 15(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗